Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects. - Wikidata - awgldk - TriplyDB

Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.

Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.

http://www.wikidata.org/entity/Q38099679

about

The Role of Levosimendan in Patients with Decreased Left Ventricular Function Undergoing Cardiac Surgery Acute right heart syndrome in the critically ill patient.Effects of a myofilament calcium sensitizer on left ventricular systolic and diastolic function in rats with volume overload heart failure Acute effects of levosimendan in experimental models of right ventricular hypertrophy and failure.Effects of Levosimendan on Patients with Heart Failure Complicating Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials.Inotropes and inodilators for acute heart failure: sarcomere active drugs in focus.Inflammation and cardiac dysfunction during sepsis, muscular dystrophy, and myocarditis.Intermittent levosimendan infusions in advanced heart failure: a real world experience.Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription.Probing the mechanism of cardiovascular drugs using a covalent levosimendan analog.[Levosimendan for septic shock with takotsubo cardiomyopathy].Comparison of Levosimendan, Milrinone and Dobutamine in treating Low Cardiac Output Syndrome Following Valve Replacement Surgeries with Cardiopulmonary Bypass.eComment. Consider trying levosimendan Acute Right Ventricular Dysfunction in Intensive Care Unit.Effect of levosimendan therapy on myocardial infarct size and left ventricular function after acute coronary occlusion.

P2860

Q28075665-AA4A7B56-2E5E-485B-A200-BEF1DCC8C72A Q30429239-0052EACE-FF5B-4ABB-B569-C7652F19F8DC Q34627826-624722C7-7B04-499E-8E2F-12CC7857CD1A Q34782515-22E429C2-8003-4BFE-81E7-25BFFE1D6948 Q36396523-186118A5-470C-4B6E-98AF-440E1E3277D7 Q38208442-696D3CE8-A130-4CC2-A44B-1CCC297D15E5 Q38940783-C1A10D7A-967B-466E-BEDE-B8247215EE20 Q38949815-2C104975-ABAC-4CA0-9D96-C3228B891DE7 Q40070005-14EADBE2-1887-4FF1-AAD5-05151A1EAED7 Q40151421-16E8FED3-089E-44A1-93AA-9B4C8B1C3F80 Q40889719-FDB9F56E-69E1-46B8-A852-3245702CA68E Q42004286-9AEB008A-462F-4987-B2DA-132682992320 Q42084852-5A31E272-2F36-4741-9AFB-01FCBCB84B49 Q47140106-89ACA6E8-00A0-4D95-AFF6-874DE71C7E2B Q47333411-983F637D-8036-448C-A27A-6C69DCF46AB2

P2860

Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.

http://www.wikidata.org/entity/Q38099679

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.

@en

type

label

Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.

@en

prefLabel

Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.

@en

P1433

Q38099679-B041BDA6-3CDA-4916-859B-5274F63A99B2

P1476

Q38099679-AD9BFE45-CA29-43DC-8E54-B3D6B70EA3EE

P2093

Q38099679-2710F249-E2B8-4941-8EA1-13D7E4356C61

Q38099679-989B6815-4F48-4280-8055-EC5B1FCC847A

Q38099679-E9D8447B-E211-47C0-9C69-1C4008C0E3CF

Q38099679-F234A119-FB1C-4BBB-B280-D4E9083CA5DF

P2860

Q38099679-01618357-9D36-4FD4-BB33-C2031492BCEF

Q38099679-06A3E3D0-2454-4933-9111-09ECFA0B264A

Q38099679-0A9AA9C5-28E6-4EF7-B342-FA8DF0A88F7A

Q38099679-0AC8C95E-C494-4DD7-9FCB-B8E94A5B0828

Q38099679-0DAEBC2D-4C1C-46E7-9139-C5A57B60AB41

Q38099679-153C93C0-FDBD-45A2-BD5E-2166D010D5D5

Q38099679-1A591970-4537-489C-9E36-75B8E2CF07DC

Q38099679-1D20B43C-233C-445E-B26C-2CBCF5EA8F9D

Q38099679-27B91232-B5DF-42B5-B98D-7AE9F4D610CF

Q38099679-2D8471BD-B8F1-4795-8F47-48FD348121D6

P304

Q38099679-5FDD435A-CDCB-4B15-81A0-A5872F6C64B5

P31

Q38099679-3F1A3AF9-EBAE-4276-9AE2-9EBA3A5AB710

P356

Q38099679-DB3B5AFC-309A-4FEF-8E64-4702D36BE0B0

P433

Q38099679-5BDF2708-B6C5-49A3-91BF-F8E289D4E4E8

P478

Q38099679-19C700B5-BC6B-4044-B228-9C8BF3D63A15

P50

Q38099679-BEA405CA-3867-4C5B-8334-94C715A203F0

P577

Q38099679-62DC1EA6-C238-486C-BF3F-14C6AC8AF5E5

P5875

Q38099679-8CB9DE4B-7849-4F0E-8866-032255687ACF

P698

Q38099679-F8B1F733-66D4-4AE7-A6E9-EA31A234067A

P921

Q38099679-EC451F41-AEA7-4683-A6C2-71C33651C1E6

P356

P1433

Journal of Clinical Pharmacy and Therapeutics

P1476

Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects

@en

P2093

A Pathak

http://www.w3.org/2001/XMLSchema#string

A Vaccaro

http://www.w3.org/2001/XMLSchema#string

F Despas

http://www.w3.org/2001/XMLSchema#string

M Lebrin

http://www.w3.org/2001/XMLSchema#string

P2860

Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE

A structural and functional perspective into the mechanism of Ca2+-sensitizers that target the cardiac troponin complex

The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig

Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial

Binding of levosimendan, a calcium sensitizer, to cardiac troponin C.

Neuroprotective properties of levosimendan in an in vitro model of traumatic brain injury.

ATP-Sensitive potassium channels: a review of their cardioprotective pharmacology.

Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology.

A glossary of circulating cytokines in chronic heart failure.

The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis.

P304

341-349

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JCPT.12067

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Michel Sénard

P577

2013-04-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236223494

http://www.w3.org/2001/XMLSchema#string

P698

23594161

http://www.w3.org/2001/XMLSchema#string

P921